Home Drug Codes J Codes J2354 · OCTREOTIDE ACETATE
Updated July 1st, 2026

OCTREOTIDE ACETATE J Code: J2354

Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for J2354, effective October 1, 2026: $0.574 per HCPCS billing unit, down 3.7% from $0.596. From CMS's final file.

?
Medicare Payment Limit ?
$0.596
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
Not published
CMS publishes none for Q3 2026
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
51
View NDC crosswalk →
Self-Administered Drug Exclusion 7 Medicare Administrative Contractors list J2354 as usually self-administered and exclude it from Part B coverage in their jurisdictions. Check the article for your MAC before billing: CGS, First Coast, Noridian (A53032), Noridian (A53033), Novitas, Palmetto, Wellpoint Federal, WPS · All SAD lists →

Drug & Product Overview

HCPCS Descriptor Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg
HCPCS Added Date January 1, 2004
Manufacturer Multiple Manufacturers
Route of Administration Intravenous, Subcutaneous
Generic Status Multi-Source; Generic
Dosage Type Single-Dose, Multi-Dose
Dosage Form Injection, Solution | Not Available

About OCTREOTIDE ACETATE

Octreotide Acetate is a medication aligned to the HCPCS J Code: J2354 for billing, pricing, and reimbursement purposes in the United States. Classified under Growth Disorder, it is administered via the intravenous or subcutaneous routes and manufactured by multiple companies.

According to CMS Drug Use Information: Octreotide is used to treat severe watery diarrhea and sudden reddening of the face and neck caused by certain types of tumors (such as carcinoid tumors, vasoactive intestinal peptide tumors) that are found usually in the intestines and pancreas. The symptoms occur when these tumors make too much of certain natural substances (hormones). This medication works by blocking the production of these hormones. By decreasing watery diarrhea, octreotide helps to reduce the loss of body fluids and minerals. Octreotide is also used to treat a certain condition (acromegaly) that occurs when the body makes too much of a certain natural substance called growth hormone. Treating acromegaly helps reduce the risk of serious problems such as diabetes and heart disease. Octreotide works by decreasing how much growth hormone your body makes. This drug is not a cure for these conditions. This medication is usually used with other treatment (such as surgery, radiation, other drugs).

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. Showing 5 of 51 NDCs — log in for the full crosswalk.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
00078-0180-01 Sandostatin Novartis Pharmaceuticals Corporation 20 50 MCG / 1 ML
00641-6174-10 Octreotide Acetate Hikma Pharmaceuticals USA Inc. 20 50 MCG / 1 ML
23155-0685-31 Octreotide Acetate Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 40 1000 MCG / 5 ML
25021-0451-01 Octreotide Acetate Sagent Pharmaceuticals 20 50 MCG
63323-0376-01 Octreotide Fresenius Kabi USA, LLC 40 100 MCG / 1 ML
•••••-••••-•• Log in to view OCTREOTIDE ACETATE
OCTREOTIDE ACETATE
OCTREOTIDE ACETATE
Login to view 46 more NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

OCTREOTIDE ACETATE Pricing & Reimbursement

J2354 Private Payer Reimbursement
$0.80 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

OCTREOTIDE ACETATE Claims Performance

Claims from Jan 2026 – Aug 2026
Claim Denial Rate 14.67%
Avg. Days to File 7.3days
Avg. Days to Pay 23.1days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J2354 claims analytics on FocalPoint →
OnPoint Oncology

OCTREOTIDE ACETATE CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
96372 Login for More Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular Login for More
96374 Login for More Therapeutic, prophylactic, or diagnostic injection (specify substance or drug), IV push, single, or initial substance/drug Login for More
Not on the CMS JW / JZ list

CMS does not include Octreotide Acetate (J2354) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J2354. Wastage billing guide →

OCTREOTIDE ACETATE Medically Unlikely Edits (MUE)

The most billing units of J2354 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 25 mcg.

Practitioner Office & Hospital Outpatient
60 units / day
= 1,500 mcg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

mcg Enter a dose to see how many billing units it is and whether it is under the limit.

OCTREOTIDE ACETATE Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Acromegaly Carcinoid Tumors Vasoactive Intestinal Peptide Tumors
Drug Class
Somatostatin Analog [EPC]Somatostatin Receptor Agonists [MoA]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.

Frequently Asked Questions

Is there an available Octreotide Acetate billing and coding guide?
Our team has not identified a manufacturer-published source of billing and coding information for OCTREOTIDE ACETATE.
Are there any available Octreotide Acetate patient assistance programs?
Our team has not identified a manufacturer-published source of patient assistance information for OCTREOTIDE ACETATE.
Where can I find Octreotide Acetate prescribing information?
OCTREOTIDE ACETATE prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date. Visit Here →
Where can I find Octreotide Acetate side effect information?
Our team has not yet identified a source of side effects information for OCTREOTIDE ACETATE. Please check back in a few weeks.
Does billing OCTREOTIDE ACETATE require JZ/JW wastage modifiers?
CMS does not include OCTREOTIDE ACETATE (J2354) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J2354. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.